HOME >> MEDICINE >> NEWS
Study sheds light on cross-species infection for BSE

A study published early online by THE LANCET provides an estimate of the compared efficiency of oral transmission of BSE to cattle and to man.

There has been uncertainty regarding the amount of BSE material that constitutes an oral infectious dose for humans. The study estimates that a person would have to eat at least 1.5kg of neural tissue from an infected animal that was just below the detection limit when tested negative at the slaughterhouse, to be at risk of developing variant Creutzfeldt-Jakob disease (vCJD).

Jean-Phillipe Deslys (Commissariat l'Energie Atomique, France) and colleagues gave two adult primates a 5g oral dose of ground brain tissue from a BSE-affected cow. One primate developed a neurological disease closely resembling vCJD 5 years after exposure, whereas the other remained free of disease. On the basis of these findings and data from other studies the investigators estimated that the efficiency of infection from cow to primate could be 7 to 20 times lower than that of intraspecies infection for cattle.

The results of the present study also suggest that the incubation period for BSE transmission from cattle to human can be more than a third longer than that of human to human transmission.

Dr Deslys states: "The present data do not provide a definitive minimum infective dose for transmission of cattle BSE to primates, but they do give enough information for a preliminary assessment of the adequacy of existing measures to protect the human food chain.

"Our results provide reassurance that BSE screening procedures combined with CNS removal are effective measures to protect the human food chain."

In an accompanying commentary James Ironside and Mark Head (National Creutzfeldt-Jakob Disease Surveillance Unit, University of Edinburgh, UK) write that the precise implications of this study for vCJD are difficult to assess since the number of animals used in the study were small and the minimum infect
'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
1-212-633-3810
Lancet
26-Jan-2005


Page: 1 2

Related medicine news :

1. Study of energy and health in Africa focuses spotlight on charcoal and forest management
2. Study shows promise in identifying kidney failure
3. Study shows patch therapy may be as effective as oral medications
4. Study shows soy is well accepted in school lunches
5. Study finds that coordinating care of chronically ill patients does not increase liability
6. Study provides new estimates of the causes of child mortality worldwide
7. Study finds factors linked to substance use disorder relapse among health care professionals
8. Study finds majority of women willing to accept cervical cancer vaccine for self and children
9. Study shows use of budesonide reduced the risk of asthma related events by 40% in children
10. Study shows risk of cardiac death after radiation for breast cancer has dramatically decreased
11. Study shows acrylamide in baked and fried food does not increase risk of breast cancer in women

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Study sheds light cross species infection for BSE

(Date:8/3/2015)... ... 03, 2015 , ... Sensato and Divurgent ... Healthcare Systems” This three-day, highly interactive and immersive workshop, has been developed ... to the tactics, techniques and practices required to design and develop highly secure ...
(Date:8/3/2015)... ... , ... A July 13 article from The Daily Mail titled "Jab ... That Can Last 'For Five Weeks'" discusses the use of stem cells to ... that harvesting stem cell-rich bone marrow from the hip, known as bone marrow stromal ...
(Date:8/3/2015)... San Ramon, CA (PRWEB) , ... August 03, ... ... a leading global insurance brokerage firm, announced today that Joe Williams has joined ... business development, sales, and delivering HUB's differentiated service model to his clients. Mr. ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... management and investigative services, has introduced a new logo and comprehensive brand ... that improve business outcomes for its customers. EMSI’s new tagline, “Powerful Information. ...
(Date:8/2/2015)... Provo, Utah (PRWEB) , ... August 03, 2015 ... ... and corporate training, will be attending and exhibiting at the Association for Healthcare ... August 7-8. , “We are pleased for the opportunity the AHDI conference ...
Breaking Medicine News(10 mins):Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2Health News:Career Step to Exhibit at AHDI Conference in Alexandria, Virginia on August 7-8 2
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, 2015 /PRNewswire/ ... primary and secondary endpoints in a phase III study ... in adult patients with chronic non-cancer pain. Naldemedine is ... This is the third Phase III trial in which ... Study results showed that a 0.2 mg tablet ...
(Date:8/3/2015)... Israel , August 3, 2015 ... it received the statistical analysis of results from a study ... the BVX-005 phase II trial which took place in 2012, ... not exist at the time of the study- in particular ... the epidemic in the United States ...
(Date:8/3/2015)... Minn. , Aug. 3, 2015  EnteroMedics Inc. (NASDAQ: ... neuroblocking therapy to treat obesity, metabolic diseases and other ... has been appointed to the Board of Directors, ... a Class II Director until the 2018 annual meeting ... Ms. McDougal has served in an executive capacity ...
Breaking Medicine Technology:Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 3EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 2EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 3
Cached News: